UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 14, 2024, Marchex, Inc. (“Marchex”) is issuing a press release and holding a conference call regarding its financial results for the fourth quarter and fiscal year ended December 31, 2023 (the “Press Release”). The full text of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Marchex is referencing non-GAAP financial information in both the Press Release and on the conference call. A reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures is contained in the attached Press Release. Disclosures regarding definitions of these financial measures used by Marchex and why Marchex’s management believes these financial measures provide useful information to investors is also included in the Press Release.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Marchex has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
MARCHEX, INC. |
|
|
|
|
Date: March 14, 2024 |
By: |
/s/ HOLLY A. AGLIO |
|
Name: |
Holly A. Aglio |
|
Title: |
Chief Financial Officer (Principal Financial Officer) |
Exhibit 99.1
Marchex Announces Fourth Quarter and Full Year 2023 Results
SEATTLE – March 14, 2024 – Marchex, Inc. (NASDAQ: MCHX), which harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration, today announced its financial results for the fourth quarter and full year ended December 31, 2023.
Q4 2023 and Full Year 2023 Financial Highlights
|
|
Q4 2022 |
|
Q4 2023 |
|
FY 2022 |
|
FY 2023 |
GAAP Revenue |
|
$ 12.3 million |
|
$ 12.4 million |
|
$ 52.2 million |
|
$ 49.9 million |
Non-GAAP Results: |
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
$ (1.7) million |
|
$ 0.1 million |
|
$ (1.4) million |
|
$ (3.4) million * |
*Adjusted EBITDA for full year 2023 includes approximately $1,620,000 of reorganization costs. Excluding these amounts would result in Adjusted EBITDA for full year 2023 totaling $(1,780,000).
Fourth Quarter Summary:
Strategic Priorities and Growth Initiatives For 2024:
“2023 was a year of great foundational progress for Marchex. We moved aggressively to position the company to take advantage of our robust conversational data and position ourselves to emerge as a leader in conversational intelligence across our core vertical markets," said Edwin Miller, CEO. "After meeting with many of our customers through 2023 and already in 2024, I firmly believe there is a significant opportunity to build a nine-figure business. This year, we are continuing to complete our key initiatives to enable Marchex to take advantage of our robust generative AI product opportunities. We are putting the pieces in place to achieve our growth ambitions and accelerate the business. Marchex is ideally positioned to help Fortune 500 businesses understand and act on their data. We are focused on driving the future of conversational AI in our verticals and opening up new avenues for growth, some of which will launch in the course of this year.
Business Outlook
The following forward-looking statements reflect Marchex's expectations as of March 14, 2024.
For the first quarter ending March 31, 2024:
For the fiscal year 2024:
“In January we saw continued pressure on conversational volumes consistent with the fourth quarter in certain verticals such as our small business resellers, which we expect to flow through in the first part of the year. However, based on the current pipeline of customers and ongoing pilots, we believe we will grow the business sequentially from the first quarter revenue levels. In addition, the completion of our infrastructure initiatives should enable us to scale our gross margins and accelerate our go-to-market initiatives in the latter half of the year, positioning Marchex for accelerating growth,” said Miller.
Management will hold a conference call, starting at 5:00 p.m. ET on Thursday, March 14, 2024, to discuss its fourth quarter and Full Year 2023, financial results and other company updates. Access to the live webcast of the conference call will be available online from the Investors section of Marchex’s website at www.marchex.com. An archived version of the webcast will also be available at the same location two hours after completion of the call.
About Marchex
Marchex harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales and marketing teams to optimize customer journey experiences across all communication channels. Through our prescriptive analytics solutions, we enable the alignment of enterprise strategy, empowering businesses to increase revenue through informed decision-making and strategic execution. Marchex provides conversational intelligence AI powered solutions for market-leading companies in many leading B2B2C vertical markets, including several of the world’s most innovative and successful brands.
Please visit http://www.marchex.com, www.marchex.com/blog or @marchex on Twitter (Twitter.com/Marchex), where Marchex discloses material information from time to time about the company, its financial information, and its business.
Forward-Looking Statements:
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, other financial guidance, acquisitions, dispositions, projected costs, prospects, plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Marchex's actual results to differ materially from those indicated by such forward-looking statements including but not limited to product demand, order cancellations and delays, competition and general economic conditions. These factors are described in greater detail in the "Risk Factors" section of our most recent periodic report and registration statement filed with the SEC. All of the information provided in this release is as of March 14, 2024, and Marchex undertakes no duty to update the information provided herein.
In the event the press release contains links to third party websites or materials, the links are provided solely as a convenience to you. Marchex is not responsible for the content of linked third-party sites or materials and does not make any representations regarding the content or accuracy thereof.
Non-GAAP Financial Information:
To supplement Marchex's consolidated financial statements presented in accordance with GAAP and to provide clarity internally and externally, Marchex uses certain non-GAAP measures of financial performance and liquidity, including Adjusted EBITDA, Adjusted OIBA, and Adjusted non-GAAP income (loss) per share. Financial analysts and investors may use Adjusted EBITDA and Adjusted OIBA to help with comparative financial evaluation to make informed investment decisions. Financial analysts and investors may use Adjusted non-GAAP income (loss) per share to analyze Marchex's financial performance since these groups have historically used EPS related measures, along with other measures, to estimate the value of a company, to make informed investment decisions, and to evaluate a company's operating performance compared to that of other companies in its industry.
Adjusted EBITDA represents net income (loss) before (1) interest, (2) income taxes, (3) amortization of intangible assets from acquisitions, (4) depreciation and amortization, (5) stock-based compensation expense, (6) acquisition and disposition-related costs, and (7) foreign government assistance subsidies. Adjusted EBITDA is an alternative measure used by our management to understand and evaluate our core operating
performance and trends, and management believes it provides meaningful supplemental information regarding the company's liquidity and ability to fund its operations and financing obligations.
Adjusted OIBA represents Adjusted EBITDA adjusted for depreciation and amortization. This measure, among other things, is another metric by which Marchex has evaluated the performance of its business, to include being the basis on which Marchex's internal budgets were based and by which Marchex's management was evaluated in 2023. This measure represents Marchex's consolidated operating results, taking into account depreciation and other intangible amortization, but excluding the effects of certain other expenses removed in arriving at Adjusted EBITDA, as detailed above.
Adjusted non-GAAP income (loss) per share represents Adjusted non-GAAP income (loss) divided by GAAP diluted shares outstanding. Adjusted non-GAAP income (loss) generally captures those items on the statement of operations that have been, or ultimately will be, settled in cash exclusive of certain items that are not indicative of Marchex’s recurring core operating results and represents net income (loss) applicable to common stockholders plus the net of tax effects of: (1) stock-based compensation expense, (2) acquisition and disposition related costs (benefit), (3) amortization of intangible assets from acquisitions, (4) interest income and other, net, and (5) foreign government assistance subsidies.
Marchex's management believes that investors should have access to, and Marchex is obligated to provide, the same set of tools that management uses in analyzing the company's results. These non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, and should not be considered in isolation, as a substitute for, or superior to, GAAP results. Marchex’s non-GAAP financial measures may be defined differently from time to time and may be defined differently than similar titled terms used by other companies, and accordingly, care should be exercised in understanding how Marchex defines its non-GAAP financial measures in this release. Marchex endeavors to compensate for the limitations of the non-GAAP measures presented by providing the comparable GAAP measure with equal or greater prominence, GAAP financial statements, and detailed descriptions of the reconciling items and adjustments, including quantifying such items, to derive the non-GAAP measure.
For further information, contact:
Trevor Caldwell
Marchex Investor Relations
Telephone: 206.331.3600
Email: ir@marchex.com
Or
MEDIA INQUIRIES
Marchex Corporate Communications
Telephone: 206.331.3434
Email: pr(at)marchex.com
MARCHEX, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||
(In Thousands) |
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
||||
Revenue |
|
$ |
12,292 |
|
|
$ |
12,395 |
|
|
$ |
52,170 |
|
|
$ |
49,910 |
|
Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Service costs (1) |
|
|
5,671 |
|
|
|
4,683 |
|
|
|
20,462 |
|
|
|
20,582 |
|
Sales and marketing (1) |
|
|
3,345 |
|
|
|
2,492 |
|
|
|
13,517 |
|
|
|
11,412 |
|
Product development (1) |
|
|
3,840 |
|
|
|
3,154 |
|
|
|
14,355 |
|
|
|
15,355 |
|
General and administrative (1) |
|
|
2,390 |
|
|
|
2,792 |
|
|
|
9,787 |
|
|
|
10,205 |
|
Amortization of intangible assets from acquisitions |
|
|
531 |
|
|
|
394 |
|
|
|
2,124 |
|
|
|
1,987 |
|
Acquisition and disposition related costs |
|
|
37 |
|
|
|
— |
|
|
|
74 |
|
|
|
12 |
|
Total operating expenses |
|
|
15,814 |
|
|
|
13,515 |
|
|
|
60,319 |
|
|
|
59,553 |
|
Loss from operations |
|
|
(3,522 |
) |
|
|
(1,120 |
) |
|
|
(8,149 |
) |
|
|
(9,643 |
) |
Interest income (expense) and other, net |
|
|
55 |
|
|
|
19 |
|
|
|
88 |
|
|
|
(173 |
) |
Loss before provision for income taxes |
|
|
(3,467 |
) |
|
|
(1,101 |
) |
|
|
(8,061 |
) |
|
|
(9,816 |
) |
Income tax expense |
|
|
107 |
|
|
|
42 |
|
|
|
184 |
|
|
|
94 |
|
Net loss applicable to common stockholders |
|
$ |
(3,574 |
) |
|
$ |
(1,143 |
) |
|
$ |
(8,245 |
) |
|
$ |
(9,910 |
) |
Basic and diluted net loss per Class A and Class B share applicable to common stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic and diluted net loss per Class A and Class B share applicable to common stockholders |
|
$ |
(0.08 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.23 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Shares used to calculate basic net loss per share applicable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Class A |
|
|
4,661 |
|
|
|
4,661 |
|
|
|
4,661 |
|
|
|
4,661 |
|
Class B |
|
|
38,042 |
|
|
|
38,059 |
|
|
|
38,560 |
|
|
|
37,960 |
|
Shares used to calculate diluted net loss per share applicable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Class A |
|
|
4,661 |
|
|
|
4,661 |
|
|
|
4,661 |
|
|
|
4,661 |
|
Class B |
|
|
42,703 |
|
|
|
42,720 |
|
|
|
43,221 |
|
|
|
42,621 |
|
(1) Includes stock-based compensation allocated as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Service costs |
|
$ |
46 |
|
|
$ |
3 |
|
|
$ |
171 |
|
|
$ |
2 |
|
Sales and marketing |
|
|
200 |
|
|
|
83 |
|
|
|
796 |
|
|
|
663 |
|
Product development |
|
|
77 |
|
|
|
20 |
|
|
|
293 |
|
|
|
114 |
|
General and administrative |
|
|
289 |
|
|
|
380 |
|
|
|
1,386 |
|
|
|
1,613 |
|
Total |
|
$ |
612 |
|
|
$ |
486 |
|
|
$ |
2,646 |
|
|
$ |
2,392 |
|
MARCHEX, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
|
|
December 31, |
|
|
December 31, |
|
||
(In Thousands) |
|
2022 |
|
|
2023 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
20,474 |
|
|
$ |
14,607 |
|
Accounts receivable, net |
|
|
8,396 |
|
|
|
7,394 |
|
Prepaid expenses and other current assets |
|
|
2,015 |
|
|
|
1,805 |
|
Total current assets |
|
|
30,885 |
|
|
|
23,806 |
|
Property and equipment, net |
|
|
4,050 |
|
|
|
2,398 |
|
Other assets, net |
|
|
973 |
|
|
|
1,482 |
|
Right-of-use lease asset |
|
|
738 |
|
|
|
1,631 |
|
Goodwill |
|
|
17,558 |
|
|
|
17,558 |
|
Intangible assets from acquisitions, net |
|
|
2,590 |
|
|
|
602 |
|
Total assets |
|
$ |
56,794 |
|
|
$ |
47,477 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
2,037 |
|
|
$ |
1,533 |
|
Accrued benefits and payroll |
|
|
3,566 |
|
|
|
3,294 |
|
Other accrued expenses and current liabilities |
|
|
3,825 |
|
|
|
3,217 |
|
Deferred revenue and deposits |
|
|
1,384 |
|
|
|
1,214 |
|
Lease liability current |
|
|
1,252 |
|
|
|
462 |
|
Total current liabilities |
|
|
12,064 |
|
|
|
9,720 |
|
Deferred tax liabilities |
|
|
233 |
|
|
|
249 |
|
Finance lease, non-current |
|
|
— |
|
|
|
421 |
|
Lease liability non-current |
|
|
385 |
|
|
|
1,217 |
|
Total liabilities |
|
|
12,682 |
|
|
|
11,607 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Class A common stock |
|
|
49 |
|
|
|
49 |
|
Class B common stock |
|
|
385 |
|
|
|
386 |
|
Additional paid-in capital |
|
|
354,999 |
|
|
|
356,666 |
|
Accumulated deficit |
|
|
(311,321 |
) |
|
|
(321,231 |
) |
Total stockholders’ equity |
|
|
44,112 |
|
|
|
35,870 |
|
Total liabilities and stockholders’ equity |
|
$ |
56,794 |
|
|
$ |
47,477 |
|
MARCHEX, INC. AND SUBSIDIARIES
(in thousands)
(unaudited)
Reconciliation of GAAP Net Loss to Adjusted EBITDA and Adjusted Operating Income (Loss) Before Amortization (OIBA)
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||
(In Thousands) |
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
||||
Net loss applicable to common stockholders |
|
$ |
(3,574 |
) |
|
$ |
(1,143 |
) |
|
$ |
(8,245 |
) |
|
$ |
(9,910 |
) |
Interest income (expense) and other, net |
|
|
(55 |
) |
|
|
(19 |
) |
|
|
(88 |
) |
|
|
173 |
|
Income tax expense |
|
|
107 |
|
|
|
42 |
|
|
|
184 |
|
|
|
94 |
|
Amortization of intangible assets from acquisitions |
|
|
531 |
|
|
|
394 |
|
|
|
2,124 |
|
|
|
1,987 |
|
Depreciation and amortization |
|
|
608 |
|
|
|
352 |
|
|
|
1,910 |
|
|
|
1,886 |
|
Stock-based compensation |
|
|
612 |
|
|
|
486 |
|
|
|
2,646 |
|
|
|
2,392 |
|
Acquisition and disposition-related costs |
|
|
37 |
|
|
|
— |
|
|
|
74 |
|
|
|
12 |
|
Foreign government paycheck assistance and rent subsidies1 |
|
|
— |
|
|
|
— |
|
|
|
(10 |
) |
|
|
— |
|
Adjusted EBITDA |
|
$ |
(1,734 |
) |
|
$ |
112 |
|
|
$ |
(1,405 |
) |
|
$ |
(3,366 |
) |
Depreciation and amortization |
|
|
608 |
|
|
|
352 |
|
|
|
1,910 |
|
|
|
1,886 |
|
Adjusted OIBA |
|
$ |
(2,342 |
) |
|
$ |
(240 |
) |
|
$ |
(3,315 |
) |
|
$ |
(5,252 |
) |
1 Includes pandemic related wage and rent relief subsidies, recognized as a reduction of wages or rent during the period received.
MARCHEX, INC. AND SUBSIDIARIES
(in thousands)
(unaudited)
Reconciliation of GAAP Net Loss per Share to Adjusted Non-GAAP Loss1
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
||||
Net loss applicable to common stockholders, diluted |
|
$ |
(0.08 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.23 |
) |
Stock-based compensation |
|
|
0.02 |
|
|
|
0.01 |
|
|
|
0.06 |
|
|
|
0.06 |
|
Acquisition and disposition-related costs (benefit) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Amortization of intangible assets from acquisitions |
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.05 |
|
|
|
0.05 |
|
Interest income and other, net |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Adjusted non-GAAP loss per share |
|
$ |
(0.05 |
) |
|
$ |
— |
|
|
$ |
(0.08 |
) |
|
$ |
(0.12 |
) |
Shares used to calculate diluted net loss per share applicable to common stockholders (GAAP) and Adjusted Non-GAAP loss per share |
|
|
42,703 |
|
|
|
42,720 |
|
|
|
43,221 |
|
|
|
42,621 |
|
1 For the purpose of computing the number of diluted shares for Adjusted non-GAAP income (loss) per share, Marchex uses the accounting guidance that would be applicable for computing the number of diluted shares for GAAP net income (loss) per share.